10
Nov

Late last week investors wound up using Intercept Pharmaceuticals as a punching bag after new data on its NASH drug for fatty liver disease raised some troubling questions about its safety and efficacy. Its stock was hit hard, forced down 30% in hours as analysts mulled the implications of potential trouble.

…read more

Source: Place your bets: Biotechs hustle along new drugs for blockbuster liver diseases

    

0 No comments